Treatment of Candidiasis Using Conventional Antifungal Drugs
– Treatment of Candidiasis Using Conventional Antifungal Drugs –
Download Treatment of Candidiasis Using Conventional Antifungal Drugs project materials: This project material is ready for students who are in need of it to aid their research.
ABSTRACT
Candidiasis is an opportunistic mycoses caused by the yeast genus Candida. The genus comprises of many species of which Candidaalbicansis the most common.
Candidiasis can cause a wide spectrum of clinical syndromes which include cutaneous candidiasis, gastrointestinal tract candidiasis, respiratory tract candidiasis, genitourinary tract candidiasis, hepatosplenic candidiasis and systemic candidiasis. Conventional antifungal drugs are drugs widely accepted for the treatment of fungal infections.
Conventional antifungal drugs used in the treatment of candidiasis belong to three (3) principal classes: the Echinocandins (caspofungin, anidulafungin and micafungin) used for the treatment of systemic candidiasis, the Azoles (fluconazole, voriconazole, posaconazole) and the Polyenes (amphotericin B) for the treatment of cutaneous and chronic mucocutaneous candidiasis.
The treatments of these Candida infections with the conventional antifungal drugs vary substantially and are based on the anatomic location of the infection.
The patients’ underlying disease and immune status, the patients’ risk factors for infection, and the specific species of Candida responsible for infection, though these species are either susceptible or resistant to the drugs, for instance, Candida krusei is susceptible to voriconazole but resistant to fluconazole.
Conventional antifungal drugs are an essential key towards the treatment of candidiasis, but require monitoring and modification to ensure adequate treatment of the disease.
INTRODUCTION
Candidiasis is an opportunistic mycoses. It is a fungal infection caused by the yeast genus Candida.Several species of the yeast Candida are capable of causing candidiasis (Brookset al., 2013).
Thegenusis composedof organisms such as Candidaalbicans(common cause of candidiasis), Candidaglabrata, Candidaparapsilosis,Candida balanitis, Candida guilliermondii,andCandidakrusei (Pfalleretal.,2007).
Candidaspecies belong to the normalmicrobiotaofanindividual’s mucosal oralcavity, gastrointestinal tract andvagina (Shaoetal.,2007),andare manifested by mucocutaneous lesions, fungemia, and sometimes focal infection of multiple sites.
Symptoms depend on the site of infection and include dysphagia, skin and mucosal lesions, blindness, vaginal symptoms (itching, burning, discharge), fever, shock, oliguria, renal shutdown, and disseminated intravascular coagulation.
Diagnosis is done by histopathology and cultures from normally sterile sites. Conventional antifungal drugs are drugs widely accepted to fight fungal organisms causing infection and diseases in humans.
In the United States, only ten (10) antifungal drugs are currently approved by the Food and Drug Administration (FDA) for the therapy of systemic fungal infections (William, 2000).
REFERENCES
Alexander, B.D., Johnson, M.D., Pfeiffer, C.D. (2013). Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Journal of Clinical Infectious Disease, 56:1724.
Bennett, J.E. (2006).Echinocandins for candidemia in adults without neutropenia. N Engl J Med; 355:1154.
Beyda, N.D., John, J., Kilic, A. (2014).FKS mutant Candida glabrata: risk factors and outcomes in patients with candidemia. Journal of Clinical Infectious Disease,59:819.
Cleveland, A.A., Farley, M.M., Harrison, L.H. (2012). Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011. Journal of Clinical Infectious Disease,55:1352.
Colombo,A.L., Ngai,A.L., Bourque, M. (2010).Caspofungin use in patients with invasive candidiasis caused by common non-albicans Candida species: review of the caspofungin database. Antimicrobial Agents Chemother,54:1864.
Costa, C.R., de Lemos, J.A., Passos, X.S., de Araujo, C.R., Cohen, A.J., Souza, L.K., Silva, M.R. (2006). Species distribution and antifungal susceptibility profile of oral Candida isolates from HIV-infected patients in the antiretroviral therapy era. Mycopathologia.162: 45–50.
Costa-de-Oliveira, S., Marcos, Miranda I., Silva, R.M. (2011).FKS2 mutations associated with decreased echinocandin susceptibility of Candida glabrata following anidulafungin therapy. Antimicrobial Agents Chemother,55:1312.
